Reducing cardiovascular risk in diabetes: The next preventive challenge
CME accredited symposium to be held at ESC Preventive Cardiology 2020 in Malaga, SpainAgenda - Apr. 2, 2020 - ESC Preventive Cardiology, Malaga, Spain
If you are attending ESC Preventive Cardiology 2020 in Malaga, Spain, you are cordially invited to attend this CME accredited symposium
Thursday, April 2, 20202: 12:15 – 13:15 hrs
- Understand the relation between T2DM & Cardiovascular Disease
- Identify the needs for novel approaches targeting T2DM in cardiovascular prevention
- Explore results from recent cardiovascular outcome trials (CVOT) in T2DM
- Discuss potential mechanisms and multifactorial effects of GLP-1 receptor agonist contributing to cardiovascular benefits
- Review results from recent GLP1 ra outcomes trials on CV and microvascular outcomes.
- Discuss practical implications from recent CVOTs on treatment and prevention strategies in patients with CV risk and T2DM.
- Introduction: Diabetes and Cardiovascular Disease, Monika Holander, MD, Utreccht, The Netherlands
- Novel insights into preventive mechanisms of new antidiabetic medication, Marc Evans, MD, Cardiff, United Kingdom
- New ESC Guidelines on diabetes and cardiovascular diseases: Implications for prevention, Francesco Cosentino, MD, Stockholm, Sweden
- Panel discussion, Richard Hobbs, MD, Oxford, United Kingdom
This programme is accredited by the European Board for Accreditation in Cardiology (EBAC) for 1 hour of external CME credit(s). Each participant should claim only those hours of credit that have actually been spent in the educational activity. The Accreditation Council for Continuing Medical Education (ACCME®) and EBAC have recognized each other’s accreditation systems as substantially equivalent.
This symposium is funded by an unrestricted educational grant received from Novo Nordisk A/S